Brought to you by 
BrainCells gets $30mm in Series B, adds another $20mm
22 Apr 2008
Executive Summary
New investor MedImmune Ventures took part in the $30mm Series B financing of BrainCells, which is redesigning small molecules to stimulate growth of new brain tissue. Existing shareholders Bay City Capital, Oxford Bioscience Partners, Technology Partners, Pappas Ventures, and NeuroVentures also participated. A MedImmune Ventures representative joined the company's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BrainCells gets $30mm in Series B, adds another $20mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice